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Abstract
Background: Previous studies have reported an excess burden of cancer and mortality in populations with chronic
hepatitis B (HBV) or C (HCV), but there are limited data comparing hospitalization rates. In this study, we compared
hospitalization rates for all causes and viral liver disease in people notified with HBV or HCV in New South Wales
(NSW), Australia.
Methods: HBV and HCV notifications were linked to their hospital (July 2000-June 2006), HIV and death records.
Standardized hospitalization ratios (SHRs) were calculated using rates for the NSW population. Random effects
Poisson regression was used to examine temporal trends.
Results: The SHR for all causes and non alcoholic liver disease was two-fold higher in the HCV cohort compared with
the HBV cohort (SHRs 1.4 (95%CI: 1.4-1.4) v 0.6 (95%CI: 0.6-0.6) and 14.0 (95%CI: 12.7-15.4) v 5.4 (95%CI: 4.5-6.4),
respectively), whilst the opposite was seen for primary liver cancer (SHRs 16.2 (95%CI: 13.8-19.1) v 29.1 (95%CI:
24.7-34.2)). HIV co-infection doubled the SHR except for primary liver cancer in the HCV/HIV cohort. In HBV and HCV
mono-infected cohorts, all cause hospitalization rates declined and primary liver cancer rates increased, whilst rates for
non alcoholic liver disease increased by 9% in the HCV cohort but decreased by 14% in the HBV cohort (P < 0.001).
Conclusion: Hospital-related morbidity overall and for non alcoholic liver disease was considerably higher for HCV
than HBV. Improved treatment of advanced HBV-related liver disease may explain why HBV liver-related morbidity
declined. In contrast, HCV liver-related morbidity increased and improved treatments, especially for advanced liver
disease, and higher levels of treatment uptake are required to reverse this trend.
Background
Chronic infection with hepatitis B virus (HBV) or hepa-
titis C virus (HCV) is associated with increased morbid-
ity and mortality. Several data linkage studies have
reported an excess burden of hepatocellular carcinoma
(HCC) and mortality, particularly from advanced liver
disease [1-5]. They also highlight an increased disease
burden associated with HBV/HIV, HCV/HIV and HBV/
HCV co-infection [2-4,6]. These population-based stu-
dies outline the relative incidence of cancer and mortal-
ity, but there are limited data comparing the impact of
HBV and HCV infection on hospitalization rates. The
one published study compared the average number of
hospitalizations for people notified with HBV and HCV
with age and sex matched controls but did not examine
rates for liver disease or trends over time [7].
There have been considerable advances in antiviral
therapy for HBV and HCV since the mid-1990s. A popu-
lation-based study examining trends in hospitalization
rates, especially for liver-related admissions, may suggest
an effect of improved therapy on disease burden. In parti-
cular, we hypothesize that trends in hospitalization rates
for advanced HBV and HCV-related liver disease may be
diverging, given that HBV therapy can be utilized in liver
failure [8-10] and has been shown to reverse decompen-
sated liver disease [11-14]. The aim of this study was,
therefore, to compare the overall burden and trends in
hospitalization rates for all causes and viral liver disease
in people notified with HBV or HCV in New South
Wales (NSW), Australia.
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Data sources
The study cohorts comprised all people notified with
acute or chronic HCV or HBV infection in NSW (popu-
lation 7 million), as recorded on the NSW Notifiable
Diseases Database (NDD) [15] between 1992 (when per-
sonal identifiers were first recorded) and 2006. These
cohorts were further divided by their co-infection status
by linkage of HCV and HBV datasets and obtaining
HIV co-infection status by linkage to NSW data from
the National HIV Registry (NHR) [16] and National
AIDS Registry (NAR) [17]. The NDD, NHR and NAR
records contain demographic information (including full
name for NDD and name code [first two letters of sur-
name and given name] for HIV and AIDS notifications)
and variables for disease code and diagnosis date.
Hospital admissions for each cohort were obtained
from the Admitted Patient Data Collection [15], a data
base which covers all inpatient admissions from all public
(including psychiatric) and private hospitals in NSW. The
data are collected by financial year (1 July to 30 June) of
separation (discharge, transfer, death, or change in
admission type within the same hospital). Each admission
includes demographic and administrative information
and diagnosis and procedure fields coded at separation
according to the 10th revision of the International Classi-
fication of Diseases-Australian Modification (ICD-
10-AM). For our analysis, admissions were categorized
by their principal (first) diagnostic code (used to record
the main condition responsible for the stay in hospital).
Three admission categories were examined: all causes,
non alcoholic liver disease (ICD-10-AM codes K71.0-
K77.8, diseases of the liver excluding alcoholic liver
disease), and primary liver cancer (ICD-10-AM codes
C22.0-C22.9, malignant neoplasms of the liver and intra-
hepatic bile ducts). Patient name has been recorded since
1 July 2000. For this reason, the study period was limited
to separations from 1 July 2000 to 30 June 2006 (the
most recent year data were available).
The Registry of Births Deaths and Marriages [15] is a
registry of all deaths (based on receipt of a medical cer-
tificate of cause of death) in NSW and includes the date
of death. We used date of death to censor a person’s
time at risk.
Linkage process
Data linkage was carried out by the Centre for Health
Record Linkage (CHeReL) [18]. The NDD, hospitaliza-
tion and death data were linked using probabilistic
record linkage methods and ChoiceMaker software [19].
A random sample of 1000 NDD records and their
matched hospitalization and death data were reviewed
b yt h eC H e R e Lw i t haf a l s ep o s i t i v er a t eo f0 . 2 %a n da
false negative rate of less than 0.1%. Full name on the
NDD data set was then recoded to name code before
linkage with the AIDS/HIV registries using deterministic
methods based on a 100% match on name code, date of
birth and sex.
Exclusions
For the study cohorts, we examined the distribution of
hospitalizations around the time of diagnosis and deter-
mined that excluding admissions before or beginning
within 14 days of the HCV or HBV diagnosis (or earliest
of the two diagnosis dates if co-infected) was sufficient to
reduce the bias towards higher rates of admission around
the time of diagnosis, as previously noted [5] (n = 38 922,
15.3%). Consistent with this, cases were considered ineli-
g i b l ei ft h e yd i e db e f o r et h es t a r to ft h es t u d yp e r i o do r
within 14 days of their diagnosis date, or were diagnosed
within 14 days of the end, or after, the study period (n =
6635, 4.8%). Cases missing their age or sex were excluded
from the eligible cohort (n = 1406, 1.1%). Duplicate and
nested hospital admissions (i.e. an admission within the
date range of another admission for the same person)
were removed from both the NSW population and
cohort admitted patient data collections (0.7% of the 12
615 230 NSW admissions and 0.9% of the 262 834
cohorts’ admissions) such that there was only one princi-
pal diagnostic code for each time period. Because of the
extremely high frequency of admissions with a principal
diagnostic code of extracorporeal dialysis (Z49.1; 9% of
the NSW and 19% of the cohorts’ admissions) we decided
to exclude them from the analysis.
Statistical analysis
Hospitalization rates were calculated using person-years
at risk as the denominator. This was calculated for each
person as the time 14 days after the HBV or HCV diag-
n o s i so rf r o mt h es t a r to ft h es t u d yp e r i o d( w h i c h e v e r
was later) until the end of the study period or death
(whichever came first). The time at risk included the
time spent in hospital as the patient was still at risk of a
new episode of care with a different principal diagnosis.
Standardized hospitalization ratios (SHRs) were calcu-
lated by comparing numbers of admissions with those
expected using hospitalization rates for the NSW popu-
lation by 5 year age group, sex and calendar year. To
account for the correlation between hospitalizations for
t h es a m ep e r s o n ,9 5 %c o n f i d e n c ei n t e r v a l s( C I s )f o r
SHRs were calculated using the method by Stukel et al
[20], and a random effects Poisson regression model
[21] was used to estimate the mean change in hospitali-
zation rates over time. An interaction term between dis-
ease cohort and time period was fitted to assess whether
hospitalization rate changes differed by cohort, with the
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Overall rates and SHRs for each admission category
were presented for all of the disease cohorts, but trends
by age group and over time were only presented where
cohort sample sizes were sufficient.
Ethics approval
Ethics approval for the use of these confidential health
data was granted by the University of NSW and the
NSW Population and Health Services Research Ethics
Committee.
Results
Description of cohorts
There were 129 472 individuals notified with HBV, HCV
or both infections eligible for the study. Of 86 501 HCV
cases, 3.7% were also notified with HBV, 0.8% with HIV
and 0.04% with both HBV and HIV. Of 46 188 HBV cases,
6.9% were also notified with HCV, 0.6% with HIV and
0.08% with both HCV and HIV. Compared with HBV
mono-infected cases, HCV mono-infected cases were
more likely to be male, have at least one hospitalization
and die during the study period (Table 1). A similar trend
was seen for cases co-infected with HBV and HCV, and
especially HIV, compared with mono-infected cohorts.
All cause hospitalizations
Compared with the NSW population, all cause hospitali-
zation rates for the HCV mono-infection cohort were
42% higher than expected. In contrast, rates for the
HBV mono-infection cohort were 37% lower than
expected (Table 2). Thus, HCV mono-infection was
associated with more than twice the burden of hospital-
related morbidity compared with HBV mono-infection.
Co-infection with either HIV or HBV/HCV added sig-
nificantly to the burden but the additional burden was
greater for HIV.
For all disease cohorts and the NSW population, all
cause hospitalization rates were highest in the 60 years
and over age group (Figure 1). However, unlike the
NSW population (which had a secondary peak in 30-39
years) all disease cohorts had a secondary peak in less
than 30 year olds, which was most pronounced for HIV
co-infection cohorts. Therefore, excess rates (SHRs) for
all disease cohorts were highest in the youngest age
group examined and decreased with age, except for the
HBV mono-infection cohort which showed no trend by
age group.
Between 2000 and 2006, hospitalization rates for all
causes declined significantly for HBV and HCV mono-
infection cohorts (Table 3), with the annual rate of
decline significantly greater for HBV than for HCV (P <
0.001). Hospitalization rates for the HCV/HIV and
HBV/HCV cohorts showed no change over time, whilst
rates for the HBV/HIV cohort declined by 15% between
2000-2003 and 2004-2006, although this decline was not
statistically significant.
Non alcoholic liver disease
The highest hospitalization rates and SHRs for non alco-
holic liver disease were in the co-infected cohorts (Table 2).
Compared with the HBV mono-infected cohort, the HCV
mono-infected cohort had significantly higher hospitaliza-
tion rates and SHRs, and non alcoholic liver disease
accounted for a higher proportion of all hospitalizations
and all liver disease-related hospitalizations in the cohort
(Table 2; P =0 . 0 0 2a n dP < 0.001, respectively).
For both the HBV and HCV mono-infection cohorts,
hospitalization rates for non alcoholic liver disease
increased with age and the highest rates and SHRs were
in the 60+ age group (Figure 2). Rates and SHRs for
HCV were higher than for HBV in all age groups, but
more than three times higher for ages 40 years and over.
Hospitalization rates for non alcoholic liver disease
demonstrated contrasting trends over time for the HBV
and HCV mono-infected cohorts, with a significant
increase in the HCV cohort and a significant decrease in
the HBV cohort (Table 3). Similarly, within the HIV
Table 1 Characteristics of people notified with hepatitis B or C or co-infected with HIV in NSW, Australia
Attribute HCV HBV HCV/HBV HCV/HIV HBV/HIV HBV/HCV/HIV
Cohort size 82 601 42 694 3179 683 277 38
Age [years] at entry into study
† median (IQR) 37 (29-44) 35 (27-44) 35 (29-43) 36 (30-41) 37 (30-44) 35 (29-42)
Males N (%) 52 016 (63) 23 105 (54) 2314 (73) 622 (91) 263 (95) 35 (92)
Diagnosed with HCV/HBV during study period N (%)
† 31 221 (38) 17 054 (40) 1479 (47) 272 (40) 93 (34) 24 (37)
Hospitalized during study period N (%)
†,‡ 33 152 (40) 12 381 (29) 1524 (48) 371 (54) 146 (53) 24 (63)
Died during study period N (%)
† 2844 (3) 755 (2) 156 (5) 73 (11) 33 (12) 9 (24)
Total person years f/up
† 404 471 206 943 15 023 3115 1278 152
Mean person years f/up per person
† 4.9 4.8 4.7 4.6 4.6 4.0
† Study period is the six years for which hospital data were available (1 July 2000-30 June 2006).
‡ Excludes admissions for extracorporeal dialysis.
IQR, Interquartile range; f/up, follow-up.
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for HIV/HCV but decreased for HIV/HBV.
Primary liver cancer
The highest hospitalization rate and SHR for primary
liver cancer was in the HIV/HBV co-infection cohort.
However, due to the small sample size the SHR was not
significantly different to that for other cohorts (Table 2).
In the mono-infected cohorts, the SHR was significantly
higher for HBV than HCV and primary liver cancer
accounted for a higher proportion of all cause and all
liver disease-related hospitalizations (P < 0.001 for
both). This was in contrast to the comparison for non
alcoholic liver disease.
For both HBV and HCV mono-infection cohorts, hos-
pitalization rates for primary liver cancer increased with
a g ea n dt h eh i g h e s tr a t e sw e r ei nt h e6 0 +a g eg r o u p
(Figure 3). Rates and SHRs for HBV were higher than
for HCV in all age groups except the 60+ age group.
Rates of hospitalization for primary liver cancer
increased significantly between 2000 and 2006 for both
the HBV and HCV mono-infection cohort (Table 3).
However, rates increased significantly faster for the HCV
than for the HBV mono-infection cohort (P = 0.028).
Discussion
Our study revealed contrasting hospital-related morbid-
ity among individuals diagnosed with HBV and HCV
infection, and that hospitalization rates were consistently
higher in all co-infected cohorts, particularly those with
HIV. The all cause and non alcoholic liver disease hos-
pitalization rates and SHRs were two-fold higher in the
HCV mono-infection cohort compared with the HBV
mono-infection cohort, with all cause rates for HBV
mono-infection even lower than in the NSW population.
In contrast, the HBV mono-infected cohort had a
Table 2 Numbers and rates of hospitalization and standardized ratios for people with hepatitis B or C by
HIV co-infection status, July 2000-June 2006
Type of admission Disease Admissions
(n)
% All
admissions
% All liver
disease
admissions
†
Rate/1000 SHR 95% CI
All cause HCV 131 707 100 - 325.6 1.4 1.4-1.4
HBV 33 264 100 - 160.7 0.6 0.6-0.6
HCV/HBV 6499 100 - 432.6 2.0 1.9-2.1
HCV/HIV 2101 100 - 674.4 3.5 3.3-3.9
HBV/HIV 616 100 - 482.2 2.4 2.0-2.7
HCV/HBV/HIV 135 100 - 887.6 4.5 3.5-5.7
Non alcoholic liver disease HCV 1632 1.2 27.3 4.0 14.0 12.7-15.4
HBV 341 1.0 17.9 1.6 5.4 4.5-6.4
HCV/HBV 111 1.7 30.8 7.4 24.6 15.7-38.5
HCV/HIV 28 1.3 35.4 9.0 28.5 15.9-51.1
HBV/HIV 18 2.9 45.0 14.1 40.0 19.4-82.6
HCV/HBV/HIV 6 4.4 100.0 39.4 123.4 61.1-249.1
Primary liver cancer HCV 625 0.5 10.4 1.5 16.2 13.8-19.1
HBV 674 2.0 35.4 3.3 29.1 24.7-34.2
HCV/HBV 50 0.8 13.9 3.3 31.9 17.5-58.3
HCV/HIV 6 0.3 7.6 1.9 18.8 5.6-62.5
HBV/HIV 12 1.9 30.0 9.4 71.1 18.3-276.7
HCV/HBV/HIV 0 0.0 0.0 0.0 - -
† Percent of all liver disease-related admissions within each disease cohort: includes non alcoholic liver disease (ICD-10-AM codes K71-77), primary liver cancer
(ICD-10-AM codes C22), viral hepatitis (ICD-10-AM codes B15-B19), and alcoholic liver disease (K70).
SHR, standardized hospitalization ratio; CI, confidence interval.
Figure 1 All cause hospitalization rates for people notified with
hepatitis B or C in NSW, Australia by their HIV co-infection
status and age group.
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close to two-fold higher than that for the HCV mono-
infected cohort. Perhaps the most notable contrast,
however, is that between 2000 and 2006 rates for non
alcoholic liver disease increased significantly in the HCV
mono-infected cohort but decreased significantly in the
HBV mono-infected cohort. Trends that were further
accentuated in the HIV co-infection cohorts and are
suggestive of an impact of improved treatment for
advanced HBV-related liver disease [8-10,12,14].
Contrasting all cause hospital-related morbidity
between the HCV and HBV infected cohorts may relate
to differing epidemiological patterns and health care utili-
zation. In Australia, it is estimated that over 80% of HCV
cases are in Australian-born injecting drug users, infected
in their young adult years, with a smaller proportion
among immigrants [22]. In contrast, it is estimated that
over 50% of HBV cases are immigrants from HBV ende-
mic countries in South-East and North-East Asia [23]
with predominant perinatal or early childhood acquisi-
tion. A high proportion of the all cause hospitalizations
amongst the HCV cohort in the less than 30 year age
group has previously been reported to be lifestyle-related
admissions such as drug and alcohol use [24]. Such fac-
tors may also explain the high rates of all cause hospitali-
zation in young adults in the HIV co-infected cohorts.
The lower rates of hospitalization in the HBV mono-
infection cohort compared with the NSW population
across all age groups may be due to a ‘healthy immigrant’
effect or lower levels of health care utilization amongst
immigrant populations [25]. If it is the latter explanation,
the comparative burden of morbidity associated with
HBV may have been underestimated. Reasons for the
downward trend in all cause hospitalization rates
between 2000 and 2006 for both the HCV and HBV
mono infected cohorts are unclear, as rates for the NSW
population increased over the same period.
Rates of hospitalization for non alcoholic liver disease
and primary liver cancer increased markedly with age in
both the HBV and HCV infected cohorts, consistent with
previous studies. In a systematic review, hepatic fibrosis
progression was found to be non linear and significantly
affected by duration of HCV infection [26]. In addition, a
large cross sectional study showed that, regardless of the
duration of HCV infection, the risk of cirrhosis increased
significantly after the age of 50 years [27]. In HBV infec-
tion, risk of cirrhosis also increases with age, particularly
after 50 years [28].
As expected, co-infection with HIV increased the bur-
den of morbidity for both the HCV and HBV cohorts.
Compared with the mono-infected cohorts, there was at
least a two-fold increase in SHRs for all three admission
Table 3 Trends in hospitalization rates between 2000 and 2006 in people with hepatitis B or C by HIV co-infection
status
Type of admission Disease Mean % change 95% CI P value
All cause HCV -1.6
† -1.9 to -1.3 < 0.001
HBV -4.6
† -5.2 to -3.9 < 0.001
HCV/HBV -0.6
† -2.1 to 0.9 0.431
HCV/HIV 0.3
‡ -8.7 to 10.2 0.953
HBV/HIV -15.1
‡ -29.4 to 2.0 0.081
Non alcoholic liver disease HCV 9.4
† 6.1 to 12.9 < 0.001
HBV -14.2
† -19.6 to -8.4 < 0.001
HCV/HBV 7.9
† -4.3 to 21.6 0.213
HCV/HIV 255.2
‡ 48.9 to 747.7 0.004
HBV/HIV -91.7
‡ -98.9 to -35.7 0.017
Primary liver cancer HCV 42.5
† 33.8 to 51.8 < 0.001
HBV 21.3
† 14.4 to 28.6 < 0.001
† Mean annual change in rate (adjusted for the correlation between hospitalizations for the same person).
‡ Rate change between July 2000-December 2003 and January 2004-June 2006 (adjusted for the correlation between hospitalizations for the same person).
CI, confidence interval.
Figure 2 Non alcoholic liver disease hospitalization rates for
people notified with hepatitis B or C mono-infection in NSW,
Australia by age group. SHR, standardized hospitalization ratio.
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HCV/HIV cohort. HIV co-infection has been shown to
be associated with an increased HBV and HCV viral load,
a higher rate of fibrosis progression and increased risk of
cirrhosis [29-35]. In addition, HIV co-infection has been
associated with higher rates of HCC than HCV and HBV
mono-infection [36].
The burden of non alcoholic liver disease was expected
have increased during 2000-2006. This is because the dis-
ease cohorts are aging, as well as continuing to expand,
albeit at a slower rate than in previous decades [37,38].
However, hospitalization rates for non alcoholic liver dis-
ease in the HBV and HBV/HIV cohorts declined during
the review period, in contrast to the (expected) upward
trend in the HCV and HCV/HIV cohorts. This is unlikely
to be due to differential changes in case finding, which
remained relatively constant over the review period, but
may suggest an impact of HBV treatment at a population
level.
There are several factors that may help to explain why
HBV treatment has impacted on liver-related morbidity at
a population level. First, therapy for HBV improved during
the study period. Although lamivudine (available since
1998) can be successfully used to treat advanced HBV-
related liver disease [12], the availability of adefovir (2004)
and entacavir (2006), both of which have a higher genetic
barrier to resistance than lamivudine, has generally lead to
better maintenance of HBV DNA suppression, a further
reduction in the risk of liver disease, and even reversal of
decompensated liver disease [11,14]. Second, HBV treat-
ment uptake improved over the study period [38]. There-
fore, even though uptake overall remains relatively low
in Australia for both HBV (5%) and HCV (1.7%) [38],
patients presenting with HBV-related advanced liver dis-
ease would be expected to have high rates of treatment
uptake and favourable outcomes [12,14]. This means that
even low levels of HBV treatment uptake may reduce
liver-related morbidity. In contrast, patients presenting
with HCV-related advanced liver disease have either poor
HCV treatment outcomes in the case of compensated cir-
rhosis [39], or are not eligible for treatment if decompen-
sated cirrhosis is present.
The greater decline in non alcoholic liver disease hospi-
talizations for the HIV/HBV cohort compared with the
HBV mono-infected cohort adds to the evidence for an
impact of HBV therapy at a population level. Tenofovir
was approved for HIV treatment in Australia in 2002,
prior to approval of adefovir (2004), entecavir (2006) or
tenofovir (2008) for HBV mono-infection. Tenofovir pro-
vides high and sustained levels of HBV DNA suppression
in HIV/HBV and HBV populations, with no described
resistance [10,40], and has been shown to lead to resolu-
tion of decompensated liver disease [13]. The earlier
introduction and high uptake of tenofovir in HIV
infected patients [38] is consistent with a more rapid
decline in non alcoholic liver disease hospitalizations
amongst the HBV/HIV co-infected cohort and with an
impact of HBV therapy at a population level.
The contrasting trends in non alcoholic liver disease
morbidity are consistent with trends for liver transplan-
tation and mortality data. U.S. liver transplant waiting
list data showed a 27% decline in HBV-related end
stage liver disease registrations between 1999 and 2006
[41]. Similarly, Australian data for 1997-2006 show a
decline in the number and proportion of transplant
recipients with HBV-related cirrhosis, in contrast to the
upward trend for HCV-related cirrhosis [37]. In addi-
tion, rates of non-HCC liver deaths in notified cases of
HBV in NSW declined by 5% while there was no
change in the HCV cohort [42]. The more pronounced
trends for hospitalization rates seen in our study may
be due to the relatively recent advances in antiviral
treatment having a more immediate impact on morbid-
ity than on mortality.
Rates of hospitalization for both HBV- and HCV-
related primary liver cancer increased during 2000-2006,
consistent with the increasing number of liver cancer
diagnoses in Australia [43,44]. A further contribution to
these trends may be increasing management options for
primary liver cancer [45]. The higher hospitalization
rates for primary liver cancer in the HBV-mono-infected
cohort compared with the HCV mono-infected cohort
may be because a higher proportion were infected at an
early age (in their country of birth) and therefore have a
greater cumulative risk of disease progression [46]. This
may also explain the high SHRs in the less than 40 year
age groups. However, only date of diagnosis (which may
occur many years after the date of infection) is reported
so we are unable to confirm what age cases were
infected. Another reason for the difference may be that
Figure 3 Primary liver cancer-related hospitalization rates for
people notified with hepatitis B or C mono-infection in NSW,
Australia by age group. SHR, standardized hospitalization ratio.
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cirrhosis due to the direct oncogenic affects of the HBV
virus [47]. Therefore, even if the overall cirrhosis risk is
similar there may be a greater risk of liver cancer in
HBV cases. Our results are consistent with other popu-
lations-based linkage studies in Australia which show
higher mortality from, and incidence of, liver cancer in
people with HBV compared to those with HCV [1,42].
The major strength of our study is that it is a large
population-based linkage study including HIV co-infec-
tion status. By linkage of the cohorts to their hospital
records we were also able to account for the correlation
between hospitalizations for the same patient in our
analyses of changes over time. The temporal trends pre-
sented here may therefore differ from the crude rate
changes reported in other studies that were unable to
account for within patient clustering or increases in the
HCV and HBV infected population [48-50].
Population-based studies have some methodological lim-
itations. In particular, caution needs to be exercised when
comparing the different cohorts as some of the differences
may be due to unmeasured confounding factors. Differ-
ences in the overall burden and trends over time may be
due to variations in health care utilization rather than dif-
ferences in actual morbidity. Second, while the aim of our
study was to examine morbidity in cases of chronic HBV
and HCV infection, more than 65% of HBV records and
77% of HCV records did not specify whether a case was
acute or chronic and only 2% and 1% of cases, respectively,
were recorded as newly acquired. For this reason all
records were included, which would lead to an underesti-
mate chronic HBV and HCV-related morbidity as some of
the notified cases may have cleared their infection. How-
ever, it is estimated that 74% HCV infections are chronic
[51] and most notified cases of HBV are also likely to be
chronic given that a high proportion are thought to have
acquired their infection in endemic countries during child-
hood [23]. Third, we were unable to exclude members of
the disease cohorts from the reference (NSW) population.
Although the cohorts only accounted for 1.5% of all cause
hospitalizations in the NSW population, they accounted for
one quarter of the liver cancer and 19% of the non alco-
holic liver disease admissions. A comparison with the non
infected population would therefore have yielded higher
SHRs. Fourth, identifiers for matching HIV cases were not
complete, so some of the HBV and HCV mono-infected
cohort may include HIV positive cases, but again this
would only lead to an underestimate of morbidity asso-
ciated with HIV co-infection. Fifth, hospital data with iden-
tifiers for linkage were only available for a six year period
from June 2000, so the trends identified here need to be
monitored for a longer period of time. Sixth, there is likely
to be some misclassification of alcoholic and non alcoholic
liver disease diagnoses. However, this misclassification is
likely to be non differential and there were no changes to
the coding procedure over the period of the review. There-
fore coding errors are unlikely to explain any divergent
trends. Finally, for some of the analyses there were too few
cases of HIV co-infected patients to examine trends.
Conclusions
Our population-based study indicates that hospital-
related morbidity overall and for non alcoholic liver dis-
ease is considerably higher in notified cases with HCV
than in those with chronic HBV and that the gap in
morbidity associated with these conditions is widening.
The decline in HBV-related liver disease may, at least in
part, be due to improved treatment of advanced HBV-
related liver disease and the greater reduction in mor-
bidity from non alcoholic liver disease in the HBV/HIV
infected cohort supports this assertion. For the HCV
infected cohort, liver-related morbidity is increasing and
improved treatments, especially for advanced liver dis-
ease, and higher levels of treatment uptake are required
to reverse this trend.
Acknowledgements
The authors would like to thank Lee Taylor, Kim Lim, and the staff at the
CHeReL (especially Katie Irvine, Anita Bobba, and Glenda Lawrence) for their
advice and conducting the data linkage. The NSW Department of Health,
especially Kate Ward, are acknowledged as the data custodians and for their
advice. We acknowledge the University of New South Wales for a Health
Data Linkage grant to support the cost of record linkage. The National
Centre in HIV Epidemiology and Clinical Research (NCHECR) is funded by the
Australian Government Department of Health and Ageing. The views
expressed in this publication do not necessarily represent the position of the
Australian Government. NCHECR is affiliated with the Faculty of Medicine,
University of New South Wales.
Authors’ contributions
The study was designed by HG and GD. Data extraction was undertaken by
HG. The analysis was conducted by HG with assistance from ML and JA. The
manuscript was drafted by HG with modifications by GD and ML. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 July 2010 Accepted: 24 January 2011
Published: 24 January 2011
References
1. Amin J, Dore GJ, O’Connell DL, Bartlett M, Tracey E, Kaldor JM, Law MG:
Cancer incidence in people with hepatitis B or C infection: a large
community-based linkage study. J Hepatol 2006, 45(2):197-203.
2. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ: Causes of death after
diagnosis of hepatitis B or hepatitis C infection: a large community-
based linkage study. Lancet 2006, 368(9539):938-945.
3. Duberg A-S, Torner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson A,
Hultcrantz R, Back E, Ekdahl K: Cause of death in individuals with chronic
HBV and/or HCV infection, a nationwide community-based register
study. J Viral Hepat 2008, 15(7):538-550.
4. McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Dillon J, Bloor M,
Robertson C, Donaghy M, Hayes P, Graham L, Goldberg DJ: A population-
based record linkage study of mortality in hepatitis C-diagnosed
Gidding et al. BMC Public Health 2011, 11:52
http://www.biomedcentral.com/1471-2458/11/52
Page 7 of 9persons with or without HIV coinfection in Scotland. Stat Methods Med
Res 2009, 18(3):271-283.
5. McDonald SA, Hutchinson SJ, Bird SM, Robertson C, Mills PR, Dillon JF,
Goldberg DJ: A record-linkage study of the development of
hepatocellular carcinoma in persons with hepatitis C infection in
Scotland. Br J Cancer 2008, 99(5):805-810.
6. Omland LH, Jepsen P, Skinhoj P, Jorgensen HL, Munster AMB, Bangsborg J,
Fenger M, Sorensen HT, Obel N: The impact of HIV-1 co-infection on
long-term mortality in patients with hepatitis C: a population-based
cohort study. HIV Medicine 2009, 10(2):65-71.
7. Steinke DT, Weston TL, Morris AD, MacDonald TM, Dillon JF: Epidemiology
and economic burden of viral hepatitis: an observational population
based study. Gut 2002, 50(1):100-105.
8. Chang T-T, Lai C-L, Kew Yoon S, Lee SS, Coelho HSM, Carrilho FJ,
Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R,
Iloeje U: Entecavir treatment for up to 5 years in patients with hepatitis
B e antigen-positive chronic hepatitis B. Hepatology 2010, 51(2):422-430.
9. Liaw Y-F, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M,
Bzowej N, Niu J, Han S-H, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G,
Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, The Globe Study Group: 2-
Year GLOBE trial results: telbivudine is superior to lamivudine in patients
with chronic hepatitis B. Gastroenterology 2009, 136(2):486-495.
10. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z,
Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K,
Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK,
Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F:
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic
hepatitis B. N Engl J Med 2008, 359(23):2442-2455.
11. Chang T-T, Liaw Y-F, Wu S-S, Schiff E, Han K-H, Lai C-L, Safadi R, Lee SS,
Halota W, Goodman Z, Chi Y-C, Zhang H, Hindes R, Iloeje U, Beebe S,
Kreter B: Long-term entecavir therapy results in the reversal of fibrosis/
cirrhosis and continued histological improvement in patients with
chronic hepatitis B. Hepatology 2010, 52(3):886-893.
12. Liaw Y-F, Sung JJY, Chow WC, Farrell G, Lee C-Z, Yuen H, Tanwandee T,
Tao Q-M, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian
Lamivudine Multicentre Study Group: Lamivudine for patients with
chronic hepatitis B and advanced liver disease. N Engl J Med 2004,
351(15):1521-1531.
13. Matthews GV, Cooper DA, Dore GJ: Improvements in parameters of end-
stage liver disease in patients with HIV/HBV-related cirrhosis treated
with tenofovir. Antiviral Therapy 2007, 12(1):119-122.
14. Schiff ER, Lai C-L, Hadziyannis S, Neuhaus P, Terrault N, Colombo M,
Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve J-P,
Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS,
Van Doren S, Fry J, Brosgart CL, The Adefovir Dipovoxil Study 435
International Investigators Group: Adefovir dipivoxil therapy for
lamivudine-resistant hepatitis B in pre- and post-liver transplantation
patients. Hepatology 2003, 38(6):1419-1427.
15. Population Health Division: The health of the people of New South Wales -
Report of the Chief Health Officer. Sydney: NSW Department of Health; 2009.
16. McDonald AM, Crofts N, Kaldor JM, National HIV Surveillance Committee: A
national surveillance system for newly acquired HIV infection in
Australia. Am J Public Health 1994, 84(12):1923-1928.
17. Kaldor J, McDonald AM, Blumer CE, Gertig DM, Patten JJ, Roberts M,
Walker CC, Mullins SE, Bailey KA, Chuah JCP: The acquired
immunodeficiency syndrome in Australia: incidence 1982 - 1991. Med J
Aust 1993, 158:10-17.
18. The Centre for Health Record Linkage. [http://www.cherel.org.au].
19. ChoiceMaker Technologies Inc: New York, NY10010 .
20. Stukel TA, Glynn RJ, Fisher ES, Sharp SM, Lu-Yao G, Wennberg JE:
Standardized rates of recurrent outcomes. Stat Med 1994,
13(17):1781-1791.
21. Kirkwood BR, Sterne JAC: Essential medical statistics. Malden,
Massachusetts: Blackwell Science Ltd;, 2 2003.
22. Razali K, Thein H, Bell J, Cooper-Stanbury M, Dolan K, Dore GJ, George J,
Kaldor JM, Karvelas M, Li J, Maher L, McGregor S, Hellard M, Poeder F,
Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M:
Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol
Depend 2007, 91(2-3):228-235.
23. O’Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ: Estimates
of chronic hepatitis B virus infection in Australia, 2000. Aust NZ J Public
Health 2004, 28(3):212-216.
24. Gidding HF, Amin J, Dore GJ, Ward K, Law MG: Hospital-related morbidity
in people notified with hepatitis C; a population-based record linkage
study in New South Wales, Australia. J Hepatol 2010, 53:43-49.
25. Singh GK, Siahpush M: Ethnic-immigrant differentials in health behaviors,
morbidity, and cause-specific mortality in the United States: an analysis
of two national data bases. Hum Biol 2002, 74(1):83-109.
26. Thein H-H, Yi Q, Dore GJ, Krahn MD: Estimation of stage-specific fibrosis
progression rates in chronic hepatitis C virus infection: a meta-analysis
and meta-regression. Hepatology 2008, 48(2):418-431.
27. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J:
Rates and risk factors of liver fibrosis progression in patients with
chronic hepatitis C. J Hepatol 2001, 34(5):730-739.
28. Iloeje UH, Yang H-I, Su J, Jen C-L, You S-L, Chen C-J, Risk Evaluation of Viral
Load E, Associated Liver Disease/Cancer-In HBVSG: Predicting cirrhosis risk
based on the level of circulating hepatitis B viral load. Gastroenterology
2006, 130(3):678-686.
29. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A,
Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T, The Multivirc Group:
Liver fibrosis progression in human immunodeficiency virus and
hepatitis C virus coinfected patients. Hepatology 1999, 30(4):1054-1058.
30. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P,
White GC, Angiolillo AL, Luban NLC, Sherman KE, Manco-Johnson M,
Preiss L, Leissinger C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW,
Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A: End-stage liver disease in
persons with hemophilia and transfusion-associated infections. Blood
2002, 100(5):1584-1589.
31. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T,
Piccinino F: Virologic and clinical expressions of reciprocal inhibitory
effect of hepatitis B, C, and delta viruses in patients with chronic
hepatitis. Hepatology 2000, 32(5):1106-1110.
32. Thein H-H, Yi Q, Dore GJ, Krahn MD: Natural history of hepatitis C virus
infection in HIV-infected individuals and the impact of HIV in the era of
highly active antiretroviral therapy: a meta-analysis. AIDS 2008,
22(15):1979-1991.
33. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van
Nhieu J, Seigneurin JM, Buffet C, Dhumeaux D: Characteristics of patients
with dual infection by hepatitis B and C viruses. JH e p a t o l1998, 28(1):27-33.
34. Bodsworth N, Donovan B, Nightingale BN: The effect of concurrent
human immunodeficiency virus infection on chronic hepatitis B: a study
of 150 homosexual men. J Infect Dis 1989, 160(4):577-582.
35. Puoti M, Torti C, Bruno R, Filice G, Carosi G: Natural history of chronic
hepatitis B in co-infected patients. J Hepatol 2006, 44(1 Suppl):S65-70.
36. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, Precone D,
Gelatti U, Asensi V, Vaccher E, Group HHCI-S: Hepatocellular carcinoma in
HIV-infected patients: epidemiological features, clinical presentation and
outcome. AIDS 2004, 18(17):2285-2293.
37. Gidding HF, Topp L, Middleton M, Robinson K, Hellard M, McCaughan G,
Maher L, Kaldor JM, Dore GJ, Law MG: The epidemiology of hepatitis C in
Australia: Notifications, treatment uptake and liver transplantations,
1997-2006. J Gast Hepatol 2009, 24(10):1648-1654.
38. National Centre in HIV Epidemiology and Clinical Research: HIV/AIDS, viral
hepatitis and sexually transmissible infections in Australia Annual Surveillance
Report 2009 University of NSW, Sydney; 2009.
39. Cheng WSC, Roberts S, Weltman M, Crawford DHG, Sievert W,
McCaughan G, Rawlinson W, Desmond P, Yoshihara M, Rizkalla B,
DePamphilis J, Marks P, Dore GJ: Efficacy and safety of Peginterferon alfa-
2A 360 μg/week in combination with ribavirin in hepatitis C genotype 1
patients with cirrhosis: analysis from the CHARIOT study. J Hepatol 2009,
50:S221.
40. Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B,
Cheng AK, Study T, Study T: Efficacy of tenofovir disoproxil fumarate in
antiretroviral therapy-naive and -experienced patients coinfected with
HIV-1 and hepatitis B virus. J Infect Dis 2004, 189(7):1185-1192.
41. Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA,
Brosgart CL: Trends in waiting list registration for liver transplantation for
viral hepatitis in the United States. Gastroenterology 2009,
137(5):1680-1686.
Gidding et al. BMC Public Health 2011, 11:52
http://www.biomedcentral.com/1471-2458/11/52
Page 8 of 942. Walter SR, Thein H-H, Amin J, Gidding HF, Ward K, Law MG, George J,
Dore GJ: Trends in mortality after diagnosis of hepatitis B or C infection:
1992-2006. J Hepatol 2010.
43. Amin J, O’Connell D, Bartlett M, Tracey E, Kaldor J, Law M, Dore G: Liver
cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage
study. Aust NZ J Public Health 2007, 31(5):475-482.
44. Alam N, Chen W, Baker D, Bishop J: Liver Cancer in New South Wales Sydney
Cancer Institute NSW; 2009.
45. Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ: Mortality and
hospital utilization for hepatocellular carcinoma in the United States.
Gastroenterology 2005, 129(2):486-493.
46. Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in
cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5 Suppl 1):
S35-50.
47. Blum HE, Moradpour D: Viral pathogenesis of hepatocellular carcinoma.
J Gastroenterol Hepatol 2002, 17(Suppl 3):S413-420.
48. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL: Trends in
health care resource use for hepatitis C virus infection in the United
States. Hepatology 2005, 42(6):1406-1413.
49. Myers RP, Liu M, Shaheen AA: The burden of hepatitis C virus infection is
growing: a Canadian population-based study of hospitalizations from
1994 to 2004. Can J Gastroenterol 2008, 22(4):381-387.
50. Thomson SJ, Westlake S, Rahman TM, Cowan ML, Majeed A, Maxwell JD,
Kang J-Y: Chronic liver disease–an increasing problem: a study of
hospital admission and mortality rates in England, 1979-2005, with
particular reference to alcoholic liver disease. Alcohol Alcohol 2008,
43(4):416-422.
51. Micallef JM, Kaldor JM, Dore GJ: Spontaneous viral clearance following
acute hepatitis C infection: a systematic review of longitudinal studies.
J Viral Hepat 2006, 13(1):34-41.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/11/52/prepub
doi:10.1186/1471-2458-11-52
Cite this article as: Gidding et al.: Trends in all cause and viral liver
disease-related hospitalizations in people with hepatitis B or C:
a population-based linkage study. BMC Public Health 2011 11:52.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gidding et al. BMC Public Health 2011, 11:52
http://www.biomedcentral.com/1471-2458/11/52
Page 9 of 9